Research programme: anti-inflammatory therapeutics - Microba Life Sciences
Latest Information Update: 24 Aug 2023
At a glance
- Originator Microba Life Sciences
- Developer Microba Life Sciences; Newcastle University; The University of Queensland
- Class Anti-inflammatories; Bacteria
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Inflammatory bowel diseases
Highest Development Phases
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 31 Jul 2023 Research programme: anti-inflammatory therapeutics - Microba Life Sciences is available for licensing as of 31 Jul 2023. https://microba.com/leadership/
- 31 Jul 2023 Preclinical trials in Inflammatory bowel diseases in Australia (unspecified route), prior to July 2023 (Microba Life Sciences pipeline, July 2023)